Uncontrolled Expression of Vascular Endothelial Growth Factor and Its Receptors Leads to Insufficient Skin Angiogenesis in Patients With Systemic Sclerosis

Systemic sclerosis (SSc) skin lesions are characterized by disturbed vessel morphology with enlarged capillaries and an overall reduction in capillary density, suggesting a deregulated, insufficient angiogenic response. It has been postulated that this phenomenon is due to reduced expression of the potent angiogenic factor vascular endothelial growth factor (VEGF). In contrast to this hypothesis, we demonstrate that the expression of both VEGF and its receptors VEGFR-1 and VEGFR-2 is dramatically upregulated in skin specimens of SSc patients throughout different disease stages. Interestingly, upregulation of VEGF was not mediated by hypoxia-inducible transcription factor-1 (HIF-1) as indicated by only a weak expression of the oxygen-sensitive &agr;-subunit of HIF-1 in the skin of SSc patients. This was unexpected on measuring low PO2 values in the SSc skin by using a polarographic oxygen microelectrode system. Considering our observation that PDGF and IL-1β costimulated VEGF expression, we propose that chronic and uncontrolled VEGF upregulation that is mediated by an orchestrated expression of cytokines rather than VEGF downregulation is the cause of the disturbed vessel morphology in the skin of SSc patients. Consequently, for therapeutic approaches aiming to improve tissue perfusion in these patients, a controlled expression and timely termination of VEGF signaling appears to be crucial for success of proangiogenic therapies.

[1]  U. Müller-Ladner,et al.  Bucillamine induces the synthesis of vascular endothelial growth factor dose-dependently in systemic sclerosis fibroblasts via nuclear factor-kappaB and simian virus 40 promoter factor 1 pathways. , 2004, Molecular pharmacology.

[2]  Maurizio Cutolo,et al.  Raynaud's phenomenon and the role of capillaroscopy. , 2003, Arthritis and rheumatism.

[3]  R. Gay,et al.  Angiogenic and angiostatic factors in the molecular control of angiogenesis. , 2003, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[4]  S. Cheung,et al.  Quantitative correlation of serum levels and tumor expression of vascular endothelial growth factor in patients with hepatocellular carcinoma. , 2003, Cancer research.

[5]  J. Korn,et al.  Fibrosis in scleroderma. , 2003, Rheumatic diseases clinics of North America.

[6]  O. Distler,et al.  Non organ based laboratory markers in systemic sclerosis. , 2003, Clinical and experimental rheumatology.

[7]  M. Gassmann,et al.  Hypoxic up-regulation of erythroid 5-aminolevulinate synthase. , 2003, Blood.

[8]  R. Macko,et al.  Increased circulating concentrations of the counteradhesive proteins SPARC and thrombospondin-1 in systemic sclerosis (scleroderma). Relationship to platelet and endothelial cell activation. , 2002, The Journal of rheumatology.

[9]  Y. Konttinen,et al.  Increased but imbalanced expression of VEGF and its receptors has no positive effect on angiogenesis in systemic sclerosis skin. , 2002, Clinical and experimental rheumatology.

[10]  M. Conforti,et al.  Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers , 2002, Arthritis research.

[11]  R. Wenger,et al.  Cellular adaptation to hypoxia: O2‐sensing protein hydroxylases, hypoxia‐inducible transcription factors, and O2‐regulated gene expression , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[12]  P. Carmeliet,et al.  Conditional switching of VEGF provides new insights into adult neovascularization and pro‐angiogenic therapy , 2002, The EMBO journal.

[13]  M. Gassmann,et al.  Physiologically low oxygen concentrations determined in fetal skin regulate hypoxia‐inducible factor 1 and transforming growth factor β3 , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[14]  A. Ogata,et al.  Clinical significance of vascular endothelial growth factor and hepatocyte growth factor in multiple myeloma , 2002, British journal of haematology.

[15]  T. Hofer,et al.  Oxygen sensing, HIF-1alpha stabilization and potential therapeutic strategies. , 2002, Pflugers Archiv : European journal of physiology.

[16]  T. Hofer,et al.  Oxygen sensing, HIF-1α stabilization and potential therapeutic strategies , 2002, Pflügers Archiv - European Journal of Physiology.

[17]  M. Gassmann,et al.  HIF‐1 is expressed in normoxic tissue and displays an organ‐specific regulation under systemic hypoxia , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  U. Müller-Ladner,et al.  Evidence of 5-lipoxygenase overexpression in the skin of patients with systemic sclerosis: a newly identified pathway to skin inflammation in systemic sclerosis. , 2001, Arthritis and rheumatism.

[19]  M. Gassmann,et al.  Induction of HIF–1α in response to hypoxia is instantaneous , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[20]  E. Manseau,et al.  Glomeruloid microvascular proliferation follows adenoviral vascular permeability factor/vascular endothelial growth factor-164 gene delivery. , 2001, The American journal of pathology.

[21]  Till Acker,et al.  Up-regulation of hypoxia-inducible factors HIF-1α and HIF-2α under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function , 2000, Oncogene.

[22]  Peter Carmeliet,et al.  VEGF gene therapy: stimulating angiogenesis or angioma-genesis? , 2000, Nature Medicine.

[23]  L. Hornez,et al.  Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis. , 2000, Arthritis and rheumatism.

[24]  M. Gassmann,et al.  Hypoxia-regulated gene expression in fetal wound regeneration and adult wound repair , 2000, Pediatric Surgery International.

[25]  G. Neufeld,et al.  Vascular endothelial growth factor (VEGF) and its receptors , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[26]  M. Gassmann,et al.  General applicability of chicken egg yolk antibodies: the performance of IgY immunoglobulins raised against the hypoxia‐inducible factor 1α , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[27]  S M Evans,et al.  Interlaboratory variation in oxygen tension measurement by Eppendorf “Histograph” and comparison with hypoxic marker , 1997, Journal of surgical oncology.

[28]  E. Leroy SYSTEMIC SCLEROSIS : A Vascular Perspective , 1996 .

[29]  C. Strange,et al.  Elevated levels of platelet derived growth factor and transforming growth factor-beta 1 in bronchoalveolar lavage fluid from patients with scleroderma. , 1995, The Journal of rheumatology.

[30]  C. Little,et al.  Exogenous vascular endothelial growth factor induces malformed and hyperfused vessels during embryonic neovascularization. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[31]  H. Dvorak,et al.  Increased expression of vascular permeability factor (vascular endothelial growth factor) in bullous pemphigoid, dermatitis herpetiformis, and erythema multiforme. , 1995, The Journal of investigative dermatology.

[32]  K. Alitalo,et al.  Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. , 1994, The Journal of biological chemistry.

[33]  Georg Breier,et al.  Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo , 1992, Nature.

[34]  M. Goto,et al.  Production of intracellular and extracellular interleukin-1 alpha and interleukin-1 beta by peripheral blood monocytes from patients with connective tissue diseases. , 1991, Annals of the rheumatic diseases.

[35]  M. Murakami,et al.  Enhanced production of interleukin-1 and tumor necrosis factor alpha by cultured peripheral blood monocytes from patients with scleroderma. , 1990, Arthritis and rheumatism.

[36]  R. Gay,et al.  Immunohistologic demonstration of platelet-derived growth factor (PDGF) and sis-oncogene expression in scleroderma. , 1989, The Journal of investigative dermatology.

[37]  T. Medsger,et al.  Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. , 1988, The Journal of rheumatology.

[38]  A. Masi Preliminary criteria for the classification of systemic sclerosis (scleroderma). , 1980, Bulletin on the rheumatic diseases.

[39]  James F. Fries,et al.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. , 1980, Arthritis and rheumatism.